Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
The investment seeks to track the investment results of the S&P Target Risk Moderate Index composed of a portfolio of underlying equity and fixed income funds intended to represent a moderate target risk allocation strategy. The fund is a fund of funds and seeks its investment objective by investing... The investment seeks to track the investment results of the S&P Target Risk Moderate Index composed of a portfolio of underlying equity and fixed income funds intended to represent a moderate target risk allocation strategy. The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 90% of its assets in the component securities of the underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model. Mehr anzeigen
ActiveOps PLC said Thursday it has raise GBP75.7 million gross for selling shareholders in its initial public offerin ...
SEATTLE, Oct. 26 /PRNewswire/ -- Koronis Pharmaceuticals, Inc. today announced the appointment of Stephen Becker, M.D., as chief medical officer. Dr. Becker joins Koronis from AnorMED...
Agreement Eliminates Development Milestones, Significantly Reduces Royalties and Restructures Sublicense Provisions SOUTH SAN FRANCISCO, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Poniard...
VANCOUVER, Sept. 7 /PRNewswire-FirstCall/ -- AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) today announced that its common shares will begin trading on September 8, 2006 on the NASDAQ Global Market of the...
VANCOUVER, Sept. 5 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (AMEX:AOM; TSX:AOM) announced that its Board of Directors, based on the recommendation of its Strategic...
VANCOUVER, Sept. 1 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (AMEX:AOM; TSX:AOM) today confirmed that Genzyme Corp. has commenced an unsolicited offer through a...
Proposed Acquisition Will Add Complementary Late-Stage Transplant Product CAMBRIDGE, Mass., Aug. 30 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) announced today that it plans to...
Considers Genzyme Proposal Undervalued VANCOUVER, Aug. 30 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (AMEX:AOM; TSX:AOM) today announced that its Board of Directors has...
VANCOUVER, Aug. 28 /PRNewswire-FirstCall/ -- AnorMED Inc. (AMEX:AOM;TSX:AOM) today announced that it has received approval from the NASDAQ Stock Market, Inc. to list its common shares on the...
VANCOUVER, Aug. 28 /PRNewswire-FirstCall/ -- AnorMED Inc. (AMEX:AOM;TSX:AOM) today announced that it has called the Company's 2006 Annual and Special Meeting of Shareholders to be held on...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.27 | -0.609205776173 | 44.32 | 44.3322 | 43.91 | 130114 | 44.07264265 | SP |
| 4 | -0.15 | -0.339366515837 | 44.2 | 44.64 | 43.76 | 113041 | 44.18010922 | SP |
| 12 | -0.24 | -0.541883043576 | 44.29 | 45.31 | 43.76 | 92567 | 44.41482513 | SP |
| 26 | 1.35 | 3.16159250585 | 42.7 | 45.31 | 42.1706 | 99551 | 43.72665741 | SP |
| 52 | 4.08 | 10.2076557418 | 39.97 | 45.31 | 39.9201 | 138521 | 42.24926131 | SP |
| 156 | -1.55 | -3.39912280702 | 45.6 | 45.73 | 35.71 | 193070 | 40.60256273 | SP |
| 260 | 4.33 | 10.9013091641 | 39.72 | 46.045 | 33.25 | 190825 | 40.87796222 | SP |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
